Physician profile
Thomas Yuen
NPI 1992867055
$5,076.35
in general payments reported to CMS, 2019-2025
26 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $55.97 · 2021: $149 · 2022: $385 · 2023: $1,129 · 2024: $1,389 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.62 | 2022-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $815.52 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $690.88 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $618.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $525.27 | 2022-2025 | |
| Gilead Sciences, INC. | $276.86 | 2019-2021 | |
| Exact Sciences Corporation | $186.64 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $166.70 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.16 | 2023-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $76.72 | 2019 | |
| Glaxosmithkline, LLC. | $75.59 | 2022-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $72.88 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $70.91 | 2023-2024 | Auvelity |
| Amgen INC. | $63.46 | 2022-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $51.84 | 2024-2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.03 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $40.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.46 | 2023 | Quviviq |
| Viiv Healthcare Company | $36.26 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.01 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.77 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.70 | 2024 | Voquezna |
| Abiomed | $26.70 | 2025 | |
| Boston Scientific Corporation | $24.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.39 | 2022 | |
| Merck Sharp & Dohme LLC | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yuen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.